Source: Annual Congress 2001 - Problems in treatment of TB
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. A. Cherenko, V. M. Petrenko, A. A. Jurilo, M. T. Klimenko (Kyiv, Ukraine). Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis. Eur Respir J 2001; 16: Suppl. 31, 2079

Member's Comments

No comment yet.

Related content which might interest you: Circulation of multidrug resistant strains of Mycobacterium tuberculosis in Abkhasia Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006 Express-diagnosing of multidrug resistant bacterial and L-forms of mycobacterium tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004 Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005 Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Resistance genotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Serbia Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017 Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002 Comorbidome in multidrug-resistant tuberculosis patients Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Outcome of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Drug resistance of Mycobacterium tuberculosis isolated from tuberculosis inflammatory foci Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015 Lipid profile in patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 361s Year: 2002 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Pulmonary tuberculosis among elderly and senile-aged patients depending on Mycobacterium strains Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Characteristics of drug susceptibility testing for bedaquline and clofazimine of 178 drug-resistant Mycobacterium tuberculosis isolates in Japan Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019 High incidence of the Beijing strains among multi drug resistance isolates of Mycobacterium tuberculosis from extra pulmonary tuberculosis cases in northern India Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012 Multi-drug resistant pulmonary tuberculosis in Belarus Source: Annual Congress 2007 - Epidemiology of various lung diseases Year: 2007 Characteristics of the cases with primary multidrug resistance pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Surgical treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009